Biotech Values

[genisi]

My original post was to counter argue against two points made by genisi and yourself. The first was that Tysabri was priced 2 fold more than Copaxone.

Regarding the 2 times fold price: I was making a point that Tysabri's introduction at such a premium, ignited aggressive price hikes from other MS drugs. I believe we agree on that.

...This was not due to some brilliant new marketing strategy of TEVA or new found wonders of Copaxone, but due to the confirmed cases of PML...

Not a wonder but in fact the clinical trials done by its rivals which proved its non-inferiority to high dose Rebif (REGARD trial) and Betaseron (BEYOND trial) do impact Copaxone utilization.

On competition - agree that there is no direct competition between Tysabri and Copaxone being used in different lines of therapy. Patients will keep failing interferons and Copacxone and there will be need for Tysabri. Question as you noted before is how will the number of patients on Tysabri grow? we also agree it depends much on future incidents of PML. Hopefully, the rate of PML will remain well below the 1 per 1000 patients, which is considered acceptable by the FDA.

Sorry I'm still talking about this, we live in different time zones and I was asleep while you and Dew posted your last arguments.